

Information on proposed Board members

Gösta Johannesson

Born 1959. B.Sc. in Business Administration and Economics. Senior adviser at Bure Equity AB. Other Board assignments: Chairman of the board in Idevall & Partners fonder, Vice Chairman of the board in Interflora AB and Axiell Group, board member in Yubico AB and others. Earlier Partner at Provider Venture Partners, before that executive position at Öhman Fondkommission and Handelsbanken Markets. Gösta Johannesson is dependent in relation to the company's major shareholders. Gösta Johannesson has been a board member since 2013. Shareholding in XVIVO Perfusion: 2 000 shares.

Folke Nilsson

Born 1950. MD, PhD. at University of Gothenburg. Specialist in Cardiothoracic surgery. Earlier responsible for Heart and Lung transplantation at Sahlgrenska Universitetssjukhuset. Currently General practitioner. No other Board assignments. Folke Nilsson is independent in relation to the company and company's major shareholders. Folke Nilsson has been a board member since 2013. Shareholding in XVIVO Perfusion: 0 shares.

Camilla Öberg

Born 1964, B.Sc. in Business Administration at Stockholm school of economics. CFO Cybercom Group from 2012 and before that CFO in Logica. Before that management positions in WM-data, SEB, Lexicon and Swegro Group. Other Board assignments: Board member in Instalco and WeSC. Camilla Öberg is independent in relation to the company and company's major shareholders. Camilla Öberg has been a board member since 2016. Shareholding in XVIVO Perfusion: 1 000 shares.

Yvonne Mårtensson

Born 1953. M. Sc. Ind. Eng. Independent Board Director and Business Advisor. Other Board assignments: Chairman of the board in Elos Medtech AB, board member in Biotage AB, SyntheticMR AB and 3Brain AG. More than thirty years' experience from leading positions in fast growing companies primarily within MedTech and diagnostic. Earlier CEO for CellaVision AB during 1998-2014. Yvonne Mårtensson is independent in relation to the company and company's major shareholders. Yvonne Mårtensson has been a board member since 2018. Shareholding in XVIVO Perfusion: 3 000 shares.

Alan Raffensperger

Born 1960. MBA from George Washington University and a B.Sc. in Health Services Management from University of Maryland Baltimore. CEO Inceptua SA. No other Board assignments. More than thirty years' experience from leading positions in fast growing companies primarily within biotech, medical device and diagnostics. Previously COO for SOBI (Swedish Orphan Biovitrum AB) during 2012-2017 and before that, during 2010-2012, CEO for Benechill Inc. Alan Raffensperger is independent in relation to the company and company's major shareholders. Alan Raffensperger has been a board member since 2018. Shareholding in XVIVO Perfusion: 0 shares.

Dag Andersson

Born 1961, MBA from INSEAD and a BA (Hons) in Business and Commerce from Stockholm School of Economics. Other Board assignments: Board member in Nolato AB (publ), GHP Specialty Care AB (publ), Terveystalo oy and Chairman of the Board in Diaverum Middle East. solid experience from the med tech and life science industry, most recently from the role as CEO for Diaverum AB during 2008-2018, and before that leading positions in Mölnlycke Health Care AB during 1993 - 2007. Dag Andersson is independent in relation to the company and company's major shareholders. Shareholding in XVIVO Perfusion: 1 000 shares.